PJB-2022-268
DETERMINATION OF HYPOGLYCEMIC, HYPOLIPIDEMIC AND NEPHROPROTECTIVE EFFECTS OF BERBERIS CALLIOBOTRYS IN ALLOXAN-INDUCED DIABETIC RATS
SHAHID RASOOL
Abstract
Many plants of Berberis genus have been reported pharmacologically to possess anti-diabetic potential and Berberis calliobotrys have been found to be inhibitor of α-glucosidase, α-amylase and tyrosinase. This study investigated hypoglycemic effects of Berberis calliobotrys methanol extract/fractions using in-vitro and in-vivo methods. BSA-methylglyoxal and BSA–glucose methods were used to assess anti-glycation activity in-vitro while, in-vivo hypoglycemic effects were determined by oral glucose tolerance test (OGTT). Moreover, the hypolipidemic and nephroprotective effects were studied and phenolics were detected using HPLC. In-vitro anti-glycation showed significant reduction in glycated end-products formation at 1, 0.25 and 0.5 mg/ml. In-vivo hypoglycemic effects were tested at 200, 400 and 600 mg/kg by measuring blood glucose, insulin, Hb and HbA1c. Synergistic effect of extract/fractions (600 mg/kg) with insulin exhibited pronounced glucose reduction in alloxan diabetic rats. The OGTT demonstrated decline in glucose concentration. Moreover, extract/fractions (600 mg/kg) exhibited improved lipid profile, increased Hb, HbA1c levels and body weight for 30 days. Furthermore, diabetic animals significantly exhibited upsurge in total protein, albumin and globulin levels while, significant improvement in urea and creatinine after extract/fractions administration for 42 days. Phytochemistry revealed alkaloids, tannins, glycosides, flavonoids, phenols, terpenoids and saponins. HPLC shown presence of phenolics in ethyl acetate fraction that could be accountable for pharmacological actions. Therefore, it can be concluded that Berberis calliobotrys possess strong hypoglycemic, hypolipidemic, nephroprotective effects and could be a potential therapeutic agent for diabetes treatment.
To Cite this article:
Download
